References
- Be couarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: Available data in non-colorectal gastrointestinal malignancies. Critical Reviews in Oncology/Hematology. 2001;40(3):265-272. http://dx.doi.org/10.1016/S1040-8428(01)00169-X
- Otsu S, Hirashima Y, Nishikawa K, Sakashita H, Morinaga R, Watanabe K, et al. Neurological toxicity in metastatic colorectal cancer patients treated with modified FOLFOX6 plus bevacizumab. Japanese Clinical Medicine. 2014;5:19-23. http://dx.doi.org/10.4137/jcm.s15553
- Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology. 2007; 3(2):281-294. http://dx.doi.org/10.1517/17425255.3.2.281
- Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: Many questions with few answers. Clinical Colorectal Cancer. 2014;13(2):73-80. http://dx.doi.org/10.1016/j.clcc.2013.11.004
- Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116. http://dx.doi.org/10.1186/1471-2407-5-116
- Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Journal of Clinical Oncology. 2004;22(23):4753-4761. http://dx.doi.org/10.1200/jco.2004.03.119
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology. 2000;18(16):2938-2947. https://doi.org/10.1200/JCO.2000.18.16.2938
- Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clinical Colorectal Cancer. 2012; 11(2):93-100. http://dx.doi.org/10.1016/j.clcc.2011.10.004
- Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology. 2014;32(10):997-1005. http://dx.doi.org/10.1200/jco.2013.52.0536
- Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003;61(9):1297-1300. http://dx.doi.org/10.1212/01.WNL.0000092015.03923.19
- Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 1998;9(7):739-744. https://doi.org/10.1023/A:1008344507482
- Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-E20. http://dx.doi.org/10.1097/NCC.0b013e31820251de
- Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: A patient perspective. Supportive Care in Cancer. 2012;20(11):2959-2967. http://dx.doi.org/10.1007/s00520-012-1428-5
- Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer. 2009;17(12):1483-1491. http://dx.doi.org/10.1007/s00520-009-0613-7
- Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clinical Colorectal Cancer. 2005;5(Suppl 1):S38-S46. http://dx.doi.org/10.3816/CCC.2005.s.006
- Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the national cancer institutesponsored clinical trials networks. Journal of Clinical Oncology. 2007;25(32):5070-5077. http://dx.doi.org/10.1200/jco.2007.12.7670
- Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nature Reviews Neurology. 2010;6(12):657-666. http://dx.doi.org/10.1038/nrneurol.2010.160
- Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology. 2007;60(1):34-42. http://dx.doi.org/10.1016/j.jclinepi.2006.03.012
- Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. Health and Quality of Life Outcomes. 2011;9:8. http://dx.doi.org/10.1186/1477-7525-9-8
- Larsen CM, Juul-Kristensen B, Lund H, Sogaard K. Measurement properties of existing clinical assessment methods evaluating scapular positioning and function. A systematic review. Physiotherapy Theory and Practice. 2014;30(7):453-482. http://dx.doi.org/10.3109/09593985.2014.899414
- Silva PF, Quintino LF, Franco J, Faria CD. Measurement properties and feasibility of clinical tests to assess sit-to-stand/stand-tosit tasks in subjects with neurological disease: A systematic review. Brazilian Journal of Physical Therapy. 2014;18(2):99-110. http://dx.doi.org/10.1590/S1413-35552012005000155
- Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investigation. 1990;8(2):147-159. https://doi.org/10.3109/07357909009017560
- Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology. 2006;33(1):15-49. http://dx.doi.org/10.1053/j.seminoncol.2005.12.010
- Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69(4):893-900. http://dx.doi.org/10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X
- Kautio AL, Haanpaa M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and national cancer institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Research. 2011;31(10):3493-3496.
- Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum. 2008;35(1):96-102. http://dx.doi.org/10.1188/08.onf.96-102
- Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005;41(8): 1135-1139. http://dx.doi.org/10.1016/j.ejca.2005.02.012
- Lee EH, Kim CJ, Kim EJ, Chae HJ, Cho SY. Measurement properties of self-report questionnaires published in Korean nursing journals. Journal of Korean Academy of Nursing. 2013;43(1): 50-58. http://dx.doi.org/10.4040/jkan.2013.43.1.50
- Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. COSMIN checklist manual [Internet]. Amsterdam, NL: COSMIN Group; 2012 [cited 2015 January 17]. Available from: http://www.cosmin.nl/images/upload/files/COSMIN%20checklist%20manual%20v9.pdf.
Cited by
- A Platinum Functional Porphyrin Conjugate: An Excellent Cancer Killer for Photodynamic Therapy vol.92, pp.4, 2015, https://doi.org/10.1246/bcsj.20180382
- A Systematic Review of Measurement Properties of Spirituality related Assessment Tools Published in Korean Journals vol.28, pp.1, 2015, https://doi.org/10.7739/jkafn.2021.28.1.133